Showing results (551-560 of 622) with videos related to

Sort By:
Pageof 63
Tribology Letters|September 17, 2025
Linear Reciprocating Tribometer for In Situ Neutron Reflectometry of Soft MatterKathryn E Shaffer, Brendan Louie Bagorio, Ahmed Al Kindi, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 26, 2017
Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa)Merrie Mosedale, Donald Button, Jonathan P Jackson, et al.
Nature Medicine|September 8, 2020
Polygenic architecture informs potential vulnerability to drug-induced liver injuryMasaru Koido, Eri Kawakami, Junko Fukumura, et al.
Clinical Pharmacology and Therapeutics|June 29, 2012
The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteersA H Harrill, J Roach, I Fier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarinsP Schmiedlin-Ren, D J Edwards, M E Fitzsimmons, et al.
Hepatology Communications|August 8, 2019
Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver InjuryHerbert L Bonkovsky, Tyler Severson, Paola Nicoletti, et al.
Clinical Pharmacology and Therapeutics|January 16, 2026
Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for FezolinetantJace C Nielsen, Jeffrey L Woodhead, Brett A Howell, et al.
Pharmacogenetics and Genomics|May 19, 2006
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humansJatinder K Lamba, Xin Chen, Lu-Bin Lan, et al.
Nature Chemistry|December 4, 2023
Subdomain dynamics enable chemical chain reactions in non-ribosomal peptide synthetasesXun Sun, Jonas Alfermann, Hao Li, et al.
Clinical Pharmacology and Therapeutics|October 23, 1997
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporineK S Lown, R R Mayo, A B Leichtman, et al.
Pageof 63